

**BIRLA INSTITUTE OF TECHNOLOGY, MESRA, RANCHI
(END SEMESTER EXAMINATION)**

**CLASS: M. PHARM.
BRANCH: PHARMACEUTICS**

**SEMESTER: I
SESSION: MO2022**

SUBJECT: MPH104T REGULATORY AFFAIRS

**TIME: 3.00 Hours
INSTRUCTIONS:**

FULL MARK: 75

1. Answer any five out of the seven questions
 2. The missing data, if any, may be assumed suitably
 3. Before attempting the question paper, be sure that you have got the correct question paper.
 4. Tables/Data hand book/Graph paper etc. to be supplied to the candidates in the examination hall.
-

- | | | |
|-----|--|-----|
| 1a. | Discuss documentation process in the pharma industry. | [7] |
| 1b. | Write notes on bioequivalence studies with pharmacokinetic endpoints. | [8] |
| 2a. | Schematically present the NDA review process. | [7] |
| 2b. | What is IMP dossier? Briefly discuss it. | [8] |
| 3a. | Write a note on drug master file. | [7] |
| 3b. | Discuss the role of in silico assays in the new drug development process. | [8] |
| 4a. | Explain the responsibilities and functional modalities of an institutional review board. | [7] |
| 4b. | Briefly explain the drug discovery process. | [8] |
| 5a. | Describe the categories and types of IND. | [7] |
| 5b. | Compare the pharmacovigilance guidelines followed in India in context to the FDA guidelines. | [8] |
| 6a. | Define medical devices and explain various regulations binding them? | [7] |
| 6b. | Define QTPP and CQA and explain with reference to a solid dosage form? | [8] |
| 7a. | Write in details the components of CTD? | [7] |
| 7b. | Enlist various quality guidelines and explain Q6 with an example? | [8] |

:::24/11/2022:::E